Trial review

Tirzepatide and PCOS: What Evidence Exists?

What exists

A mechanistic rationale, an established benefit from weight reduction in PCOS, and trials underway — including the RESTORE programme examining semaglutide's role in restoring ovulation in youth and adults with PCOS.

What does not exist is a completed body of randomised evidence establishing that GLP-1s outperform existing management on PCOS-specific outcomes, and nothing specific to tirzepatide.

Why the rationale is reasonable

PCOS commonly involves insulin resistance, and weight reduction is established first-line management where weight is a factor. Metformin has been used off-label on the same reasoning for decades. A drug acting on both insulin resistance and weight is a coherent candidate.

The interesting endpoint is ovulation rather than weight, because it tests whether benefit runs beyond the scale — with implications for cycle regularity, endometrial protection and fertility.

The point that belongs before the first dose

If treatment restores ovulation in someone who has not been ovulating, fertility may return — possibly before they expect it, and without the signals they would recognise.

GLP-1 receptor agonists are not recommended during pregnancy, and the tirzepatide label notes potential fetal harm. So a treatment that could restore fertility, in a drug that should not continue in pregnancy, creates a contraception conversation that has to happen at the start rather than after a positive test.

This is the single most practically important thing on this page, and it is routinely absent from PCOS-adjacent GLP-1 marketing.

Questions for a clinician

1. Is this being prescribed off-label for PCOS, and what does the evidence actually support?
2. If I am not currently ovulating, what happens if treatment changes that?
3. What contraception plan applies while I take this?
4. If I want to conceive, how far in advance do I stop and what do I switch to?
5. How does this compare with metformin or other options for my presentation?

What is not established

Whether GLP-1s improve live birth rates. Whether benefit persists after stopping. Whether they outperform existing management. And nothing at all about compounded preparations, microdoses or oral formulations in a PCOS population.

Questions readers actually ask

Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.